I read with great interest the report of Stiff and Vasilakos on the effects of in vivo T-cell depletion on immunity to Eimeria falciformis (8) . Their conclusion that depleting effector T-cell function results in an abrogation of protective immunity to E. falciformis is important but is contingent on their assertion that T cells are functionally deleted in the anti-Thy-1.2 (and complement)-treated mice. This the paper does not demonstrate. In fact, the data indicate only a mild reduction (-50%) in mitogen-driven T-cell responses following intravenous injections of anti-Thy-1.2 ascites and rabbit complement. These proliferative responses, ranging from 5.5 x 104 to 7.5 x 104 cpm in the data presented, are indicative of very strong T-cell function in "T-cell-depleted" mice. I suggest that analysis of Thy-i-expressing cells in these mice by flow cytometry would yield values not markedly lower than those observed in controls.
Secondly, the mitogen response appears to have been measured only at 24 h posttreatment. Most investigators find that chronic repetitive administration of monoclonal antibody is necessary to maintain satisfactory depletion of lymphocyte subsets in vivo. Characterizing T-cell function at 24 h and following disease progression over the following 20-to 25-day period is very much open to question. A correlation between loss of T-cell function in vivo and abrogation of protective immunity requires the demonstration that T-cell immunity is not present (or is very greatly reduced) throughout the time course of the study.
Selective depletion methods using antibodies directed against subset-specific determinants (administered in the absence of xenogenic complement) is a technique of great utility in delineating the in vivo role of different lymphocyte subsets. For reasons unknown, some lymphocyte populations are relative easily depleted (i.e., CD4 T cells with GK 1.5 [2] or YTS 191.1 [1] , CD8 T cells with 2.43 (7) or YTS 169.4 (1) , and B cells with polyclonal anti-,. [3, 4, 6] ), while others are comparatively resistant (i.e., CD3 T cells with 145-2C11 alone [5] or T cells with anti-Thy-1). The mechanism by which functional deletion of these lymphocyte subsets is achieved remains unresolved but appears to be almost certainly complement independent. 
